Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Manisha H. Shah, MD
|
|
Give Review
Manisha H. Shah, MD practices Oncology. She went to N.H.L Municipal Medical College. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Manisha H. Shah has written publications. She has 39 publications published with PubMed. The lastest publication is: 'Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.'
Publications
- Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.
- Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.
- The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal TransDuction in Human Immune Cells.
- Bone metastases and skeletal-related events from neuroendocrine Tumors.
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary T...
- Lenvatinib versus placebo in radioiodine-refractory thyroid Cancer.
- Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT...
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
- Bone Metastases in Well-to-Moderately Differentiated Neuroendocrine Tumors: A Single Institutional Review From the Ohio State University Medical Center.
- New era for treatment in differentiated thyroid Cancer.
- An update on clinical trials of targeted therapies in thyroid Cancer.
- Extrahepatic Disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.
- Liver-directed therapies in patients with advanced neuroendocrine tumors.
- Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.
- Sorafenib and Mek Inhibition are Synergistic in Medullary Thyroid Carcinoma in Vitro.
- Thyroid Cancer: pathogenesis and targeted therapy.
- Role of BRAF in Thyroid Oncogenesis.
- Targeting RET receptor tyrosine kinase activation in Cancer.
- A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid Tumors.
- Prospects for small interfering RNA therapeutics in thyroid Cancer.
- Reply to A. Machens et al.
- Phase II clinical trial of sorafenib in metastatic medullary thyroid Cancer.
- Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine Tumors after failure of cytotoxic chemotherapy: a phase II trial.
- Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
- Phase II trial of sorafenib in metastatic thyroid Cancer.
- G3139 (Genasense) in patients with advanced Merkel cell carcinoma.
- Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid Carcinoma.
- Tissue and serum alpha 2-3- and alpha 2-6-linkage specific sialylation changes in Oral carcinogenesis.
- E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric Cancer.
- Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE.
- Gastrointestinal stromal tumors involving the proState: presentation, course, and therapeutic approach.
- Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned.
- CytoreDuction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas.
- A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and Cancer.
- Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine Tumors.
- Phase II study of celecoxib in metastatic differentiated thyroid Carcinoma.
- Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine Tumors.
- A Study of Various Sociodemographic Factors and Plasma Vitamin Levels in Oral and Pharyngeal Cancer in Gujarat, India.
Schools
Psg Institute Of Medical Sciences and Research Tamil Nadu Dr Mgr Medical University
Buffalo Genl Hospital SUNY
Roswell Park Cancer Institute Suny Buffalo
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
N.H.L Municipal Medical College
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1679581896 | |
| NPPES Provider LastName | SHAH | |
| NPPES Provider FirstName | MANISHA | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 664.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 184.0 | |
| Percent Opioid Claims | 27.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679581896 |
| Last Name Of The Provider | SHAH |
| First Name Of The Provider | MANISHA |
| View All |
Similar Doctors
|
Dr. J Paul Monk III, MD |
|
Dr. Mark E. Thompson, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven M. Devine, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Erin M. Olson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent C. Behrens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Taral K. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Woyach, MD
This Doctor is OpenDoctor Recommended.
|